Skip to main content
Top
Published in: Rheumatology International 7/2006

01-05-2006 | Original Article

Synovial proinflammatory cytokines and their correlation with matrix metalloproteinase-3 expression in Behçet’s disease. Does interleukin-1β play a major role in Behçet’s synovitis?

Authors: Salih Pay, Hakan Erdem, Aysel Pekel, Ismail Simsek, Ugur Musabak, Ali Sengul, Ayhan Dinc

Published in: Rheumatology International | Issue 7/2006

Login to get access

Abstract

The objective of this study has been the well established fact that proinflammatory cytokines and metalloproteinases play a crucial role in the pathogenesis of chronic arthritis as well as the development of pannus, with the eventual erosive changes. Among the proinflammatory cytokines, interleukin-18 (IL-18) has been shown to contribute to the pathogenesis of chronic synovitis by increasing the secretion of interleukin-1beta (IL-1β) and the tumor necrosis factor-alpha (TNF-α) and also stimulating angiogenesis. The aim of this study is to investigate the synovial IL-18, IL-1β, TNF-α and matrix metalloproteinase-3 (MMP-3) levels in patients with Behçet’s disease (BD), and compare them with the levels of patients with rheumatoid arthritis (RA) and osteoarthritis (OA). 30 patients with BD, 20 with RA, and 20 with OA were included in the study. The synovial levels of IL-18, IL-1β, TNF-α and MMP-3 were detected using the two-step sandwich ELISA method. The synovial IL-18, TNF-α and MMP-3 levels were significantly higher in RA patients than patients with BD (P=0.004, 0.019, 0.025, respectively) and with OA (P=0.004, 0.045, 0.032, respectively). There were no differences, with respect to the cytokine levels, when patients with BD were compared with those with OA. Patients with RA and BD had higher IL-1β levels than patients with OA (P=0.017, 0.013, respectively). However, no such difference was found for IL-1β between BD and RA patients. Among patients with RA, positive correlations were found between TNF-α and MMP-3 (r=0.683, P=0.001). Our results showed that MMP-3 and proinflammatory cytokines, except IL-1β, were expressed in relatively small quantities in Behçet’s synovitis. Detection of the lower levels of these cytokines and metalloproteinases might explain the non-erosive character of Behçet’s arthritis. We suggest that IL-1β may be involved in the pathogenesis of Behçet’s synovitis.
Literature
1.
go back to reference Yamamura M, Kawashima M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, Morita Y, Ohmoto Y, Makino H (2001) Interferon-gamma-inducing activity of interleukin-18 in the joint with rheumatoid arthritis. Arthritis Rheum 44:275–285CrossRefPubMed Yamamura M, Kawashima M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, Morita Y, Ohmoto Y, Makino H (2001) Interferon-gamma-inducing activity of interleukin-18 in the joint with rheumatoid arthritis. Arthritis Rheum 44:275–285CrossRefPubMed
2.
go back to reference Dinerallo CA (2002) The IL-1 family and inflammatory diseases. Clin Exp Rheumatol 20(Suppl27):S1–S13 Dinerallo CA (2002) The IL-1 family and inflammatory diseases. Clin Exp Rheumatol 20(Suppl27):S1–S13
4.
go back to reference Cristy CP, Jacques CMM, Amin MA, Matthew AC (2001) Evidence of IL-18 as a novel angiogenic mediator. J Immunol 167:1644–1653PubMed Cristy CP, Jacques CMM, Amin MA, Matthew AC (2001) Evidence of IL-18 as a novel angiogenic mediator. J Immunol 167:1644–1653PubMed
5.
go back to reference Morel JC, Park CC, Kumar P, Koch AE (2001) Interleukin-18 induces rheumatoid arthritis synovial fibroblast CXC chemokine production through NF kappa B activation. Lab Invest 81:1371–1383PubMed Morel JC, Park CC, Kumar P, Koch AE (2001) Interleukin-18 induces rheumatoid arthritis synovial fibroblast CXC chemokine production through NF kappa B activation. Lab Invest 81:1371–1383PubMed
6.
go back to reference Joosten LA, Radstake TR, Lubberts E, Van den Bersselaar LA, Van Riel PL, Van Lent PL, Barrera P, Van den Berg WB (2003) Association of interleukin-18 expression with enhanced levels of both interleukin-1 beta and tumor necrosis factor alpha in knee synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum 48:339–347CrossRefPubMed Joosten LA, Radstake TR, Lubberts E, Van den Bersselaar LA, Van Riel PL, Van Lent PL, Barrera P, Van den Berg WB (2003) Association of interleukin-18 expression with enhanced levels of both interleukin-1 beta and tumor necrosis factor alpha in knee synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum 48:339–347CrossRefPubMed
7.
go back to reference Leung BP, Culshaw S, Gracie JA, Hunter D, Canetti CA, Campbell C, Cunha F, Liew FY, McInnes IB (2001) A role for IL-18 in neutrophil activation. J Immunol 167:2879–2886PubMed Leung BP, Culshaw S, Gracie JA, Hunter D, Canetti CA, Campbell C, Cunha F, Liew FY, McInnes IB (2001) A role for IL-18 in neutrophil activation. J Immunol 167:2879–2886PubMed
8.
go back to reference Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H (2001) Interleukin-18 regulates both Th1 and Th2 responses. Ann Rev Immunol 19:423–474CrossRef Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H (2001) Interleukin-18 regulates both Th1 and Th2 responses. Ann Rev Immunol 19:423–474CrossRef
9.
go back to reference Gracie JA (2004) Interleukin-18 as a potential target in inflammatory arthritis. Clin Exp Immunol 136:402–404CrossRefPubMed Gracie JA (2004) Interleukin-18 as a potential target in inflammatory arthritis. Clin Exp Immunol 136:402–404CrossRefPubMed
10.
go back to reference Yoshihara Y, Nakamura H, Obata K, Yamada H, Hayakawa T, Fujikawa K, Okada Y (2000) Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis 59:455–461CrossRefPubMed Yoshihara Y, Nakamura H, Obata K, Yamada H, Hayakawa T, Fujikawa K, Okada Y (2000) Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis 59:455–461CrossRefPubMed
11.
go back to reference Ribbens C, Andre B, Kaye O, Kaiser MJ, Bonnet V, Jaspar JM, de Groote D, Franchimont N, Malaise MG (2000) Synovial fluid matrix metalloproteinase-3 levels are increased in inflammatory arthritides whether erosive or not. Rheumatology 39:1357–1365CrossRefPubMed Ribbens C, Andre B, Kaye O, Kaiser MJ, Bonnet V, Jaspar JM, de Groote D, Franchimont N, Malaise MG (2000) Synovial fluid matrix metalloproteinase-3 levels are increased in inflammatory arthritides whether erosive or not. Rheumatology 39:1357–1365CrossRefPubMed
12.
go back to reference Ribbens C, Porras MM, Fanchimont N, Kaiser MJ, Jaspar JM, Damas P, Houssiau FA, Malaise MG (2002) Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 61:161–166CrossRefPubMed Ribbens C, Porras MM, Fanchimont N, Kaiser MJ, Jaspar JM, Damas P, Houssiau FA, Malaise MG (2002) Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 61:161–166CrossRefPubMed
13.
go back to reference Tchetverikov I, Lard LR, DeGroot J, Verzijl N, TeKoppele JM, Breedveld FC, Huizinga TWJ, Hanemaaijer R (2003) Matrix metalloproteinases-3,-8,-9 as markers of disease activity and joint damage progression in early rheumatoid arthritis. Ann Rheum Dis 62:1094–1099CrossRefPubMed Tchetverikov I, Lard LR, DeGroot J, Verzijl N, TeKoppele JM, Breedveld FC, Huizinga TWJ, Hanemaaijer R (2003) Matrix metalloproteinases-3,-8,-9 as markers of disease activity and joint damage progression in early rheumatoid arthritis. Ann Rheum Dis 62:1094–1099CrossRefPubMed
14.
go back to reference Masuhara K, Nakai T, Yamaguchi K, Yamasaki S, Sasaguri Y (2002) Significant increases in serum and plasma concentrations of matrix metalloproteinases-3 and 9 in patients with rapidly destructive osteoarthritis of the hip. Arthritis Rheum 46:2625–2631CrossRefPubMed Masuhara K, Nakai T, Yamaguchi K, Yamasaki S, Sasaguri Y (2002) Significant increases in serum and plasma concentrations of matrix metalloproteinases-3 and 9 in patients with rapidly destructive osteoarthritis of the hip. Arthritis Rheum 46:2625–2631CrossRefPubMed
15.
go back to reference Gattorno M, Vignola S, Falcini F, Sabatini F, Buoncompagni A, Simonini G, Picco P, Pistoia V (2002) Serum and synovial fluid concentrations of matrix metalloproteinases-3 and its tissue inhibitor 1 in juvenile idiopathic arthritides. J Rheumatol 29:826–831PubMed Gattorno M, Vignola S, Falcini F, Sabatini F, Buoncompagni A, Simonini G, Picco P, Pistoia V (2002) Serum and synovial fluid concentrations of matrix metalloproteinases-3 and its tissue inhibitor 1 in juvenile idiopathic arthritides. J Rheumatol 29:826–831PubMed
16.
go back to reference International Study Group for Behcet’s Disease (1990) Criteria for diagnosis of Behcet’s disease. Lancet 335:1078–1080 International Study Group for Behcet’s Disease (1990) Criteria for diagnosis of Behcet’s disease. Lancet 335:1078–1080
17.
go back to reference Calabrese LH, Michel BA, Bloch DA (1990) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 33:1108–1113PubMedCrossRef Calabrese LH, Michel BA, Bloch DA (1990) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 33:1108–1113PubMedCrossRef
18.
go back to reference Altman RD (1991) Criteria for classification of clinical osteoarthritis. J Rheumatol 18:10–12 Altman RD (1991) Criteria for classification of clinical osteoarthritis. J Rheumatol 18:10–12
19.
go back to reference Dai SM, Matsuno H, Nakamura H, Nishioka K, Yudoh K (2004) Interleukin-18 enhances monocyte tumor necrosis factor alpha and, interleukin-1 beta production induced by contact with T Iymphocytes: implications in rheumatoid arthritis. Arthritis Rheum 50:432–443CrossRefPubMed Dai SM, Matsuno H, Nakamura H, Nishioka K, Yudoh K (2004) Interleukin-18 enhances monocyte tumor necrosis factor alpha and, interleukin-1 beta production induced by contact with T Iymphocytes: implications in rheumatoid arthritis. Arthritis Rheum 50:432–443CrossRefPubMed
20.
go back to reference Futani H, Okayama A, Matsui K, Kashiwamura S, Sasaki T, Hada T, Nakanishi K, Tateishi H, Maruo S, Okamura H (2002) Relation between interleukin-18 and PGE2 in synovial fluid of osteoarthritis: a potential therapeutic target of cartilage degradation. J Immunother 25(Suppl1):S61–S64CrossRefPubMed Futani H, Okayama A, Matsui K, Kashiwamura S, Sasaki T, Hada T, Nakanishi K, Tateishi H, Maruo S, Okamura H (2002) Relation between interleukin-18 and PGE2 in synovial fluid of osteoarthritis: a potential therapeutic target of cartilage degradation. J Immunother 25(Suppl1):S61–S64CrossRefPubMed
21.
go back to reference Morel JC, Park CC, Woods JM, Koch AE (2001) A novel role for interleukin-18 in adhesion molecule induction through NF kappa B and phosphatidylinositol (PI) 3-kinase-dependent signal transduction pathways. J Biol Chem 276:37069–37075, Epub Morel JC, Park CC, Woods JM, Koch AE (2001) A novel role for interleukin-18 in adhesion molecule induction through NF kappa B and phosphatidylinositol (PI) 3-kinase-dependent signal transduction pathways. J Biol Chem 276:37069–37075, Epub
22.
go back to reference Smeets TJ, Barg EC, Kraan MC, Smith MD, Breedveld FC, Tak PP (2003) Analysis of the cell infiltrate and expression of proinflammatory cytokines and matrix metalloproteinases in arthroscopic synovial biopsies: comparison with synovial samples from patients with end stage, destructive rheumatoid arthritis. Ann Rheum Dis 62:635–638CrossRefPubMed Smeets TJ, Barg EC, Kraan MC, Smith MD, Breedveld FC, Tak PP (2003) Analysis of the cell infiltrate and expression of proinflammatory cytokines and matrix metalloproteinases in arthroscopic synovial biopsies: comparison with synovial samples from patients with end stage, destructive rheumatoid arthritis. Ann Rheum Dis 62:635–638CrossRefPubMed
23.
go back to reference Kageyama Y, Miyamoto S, Ozeki T, Hiyohsi M, Suzuki M, Nagano A (2000) Levels of rheumatoid factor isotypes, metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 in synovial fluid from various arthritides. Clin Rheumatol 19:14–20CrossRefPubMed Kageyama Y, Miyamoto S, Ozeki T, Hiyohsi M, Suzuki M, Nagano A (2000) Levels of rheumatoid factor isotypes, metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 in synovial fluid from various arthritides. Clin Rheumatol 19:14–20CrossRefPubMed
24.
go back to reference Gotoh H, Obata K, Yamada H, Yoshihara Y, Kikuchi Y, Shinmei M (1997) Levels of matrix metalloproteinases-3 and urokinase-type plasminogen activator in knee synovial fluids from patients with rheumatoid arthritis and osteoarthritis. Ryumachi 37:1–8 Gotoh H, Obata K, Yamada H, Yoshihara Y, Kikuchi Y, Shinmei M (1997) Levels of matrix metalloproteinases-3 and urokinase-type plasminogen activator in knee synovial fluids from patients with rheumatoid arthritis and osteoarthritis. Ryumachi 37:1–8
25.
go back to reference Ishiguro N, Ito T, Obata K, Fujimoto N, Iwata H (1996) Determination of stromelysin-1, 72 and 92 kDa type IV collagenase, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-2 in synovial fluid and serum from patients with rheumatoid arthritis. J Rheumatol 23:1599–1604PubMed Ishiguro N, Ito T, Obata K, Fujimoto N, Iwata H (1996) Determination of stromelysin-1, 72 and 92 kDa type IV collagenase, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-2 in synovial fluid and serum from patients with rheumatoid arthritis. J Rheumatol 23:1599–1604PubMed
26.
go back to reference Sasaki S, Iwata H, Ishiguro N, Obata K, Miura T (1994) Detection of stromelysin in synovial fluid and serum from patients with rheumatoid arthritis and osteoarthritis. Clin Rheumatol 13:228–233PubMed Sasaki S, Iwata H, Ishiguro N, Obata K, Miura T (1994) Detection of stromelysin in synovial fluid and serum from patients with rheumatoid arthritis and osteoarthritis. Clin Rheumatol 13:228–233PubMed
27.
go back to reference Catrina AI, Lampa J, Ernestam S, Klint E, Bratt J, Klareskog L, Ulfgren AK (2002) Anti-tumour necrosis factor (TNF)-therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology 41:484–489CrossRefPubMed Catrina AI, Lampa J, Ernestam S, Klint E, Bratt J, Klareskog L, Ulfgren AK (2002) Anti-tumour necrosis factor (TNF)-therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology 41:484–489CrossRefPubMed
28.
go back to reference Elkayam O, Yaron I, Shirazi I, Judovitch R, Caspi D, Yaron M (2003) Active leflunomide metabolite inhibits interleukin 1, tumour necrosis factor, nitrite oxide, and metalloproteinase-3 production in activated human synovial tissue cultures. Ann Rheum Dis 62:440–443CrossRefPubMed Elkayam O, Yaron I, Shirazi I, Judovitch R, Caspi D, Yaron M (2003) Active leflunomide metabolite inhibits interleukin 1, tumour necrosis factor, nitrite oxide, and metalloproteinase-3 production in activated human synovial tissue cultures. Ann Rheum Dis 62:440–443CrossRefPubMed
29.
go back to reference Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J (2004) Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis. J Rheumatol 31:238–242PubMed Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J (2004) Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis. J Rheumatol 31:238–242PubMed
30.
go back to reference Pay S, Erdem H, Serdar M, Dine A, Simsek I, Turan M (2002) Comparison of synovial MMP-1 and TIMP-1 levels in patients with various inflammatory arthritides: is there any difference between rheumatoid arthritis, Behcet’s disease and familial Mediterranean fever? Clin Rheumatol 21:511–515CrossRefPubMed Pay S, Erdem H, Serdar M, Dine A, Simsek I, Turan M (2002) Comparison of synovial MMP-1 and TIMP-1 levels in patients with various inflammatory arthritides: is there any difference between rheumatoid arthritis, Behcet’s disease and familial Mediterranean fever? Clin Rheumatol 21:511–515CrossRefPubMed
31.
go back to reference Hamzaoul K, Hamzaoul A, Guemira F, Bessioul M, Hamza M, Ayed K (2002) Cytokine profile in Behçet’s disease patients. Scand J Rheumatol 31:205–210CrossRefPubMed Hamzaoul K, Hamzaoul A, Guemira F, Bessioul M, Hamza M, Ayed K (2002) Cytokine profile in Behçet’s disease patients. Scand J Rheumatol 31:205–210CrossRefPubMed
32.
go back to reference Hamzaoui A, Ghrairi H, Ammar J, Zekri S, Guemira F, Hamzaoui K (2003) IL-8 mRNA expression and IFN-gamma induction in bronchoalveolar lavage from Behcet’s disease. Clin Exp Rheumatology 21(Suppl30):S8–S14 Hamzaoui A, Ghrairi H, Ammar J, Zekri S, Guemira F, Hamzaoui K (2003) IL-8 mRNA expression and IFN-gamma induction in bronchoalveolar lavage from Behcet’s disease. Clin Exp Rheumatology 21(Suppl30):S8–S14
33.
go back to reference Tchetverikov I, Ronday HK, van El B, Kiers GH, Verzijl N, TeKoppele JM, Huizinga TWJ, DeGroot J, Hanemaaijer R (2004) MMP profile in paired serum and synovial fluid samples of patient with rheumatoid arthritis. Ann Rheum Dis 63:881–883CrossRefPubMed Tchetverikov I, Ronday HK, van El B, Kiers GH, Verzijl N, TeKoppele JM, Huizinga TWJ, DeGroot J, Hanemaaijer R (2004) MMP profile in paired serum and synovial fluid samples of patient with rheumatoid arthritis. Ann Rheum Dis 63:881–883CrossRefPubMed
34.
go back to reference Erdem H, Pay S, Serdar M, Şimşek İ, Dinç A, Pekel A, Muşabak U, Turan M (2004). Different ELR (+) angiogenic CXC chemokine profiles in synovial fluid of patients with Behçet’s disease, familial Mediterranean fever, rheumatoid arthritis and osteoarthritis. Rheum Int (in press) Erdem H, Pay S, Serdar M, Şimşek İ, Dinç A, Pekel A, Muşabak U, Turan M (2004). Different ELR (+) angiogenic CXC chemokine profiles in synovial fluid of patients with Behçet’s disease, familial Mediterranean fever, rheumatoid arthritis and osteoarthritis. Rheum Int (in press)
35.
go back to reference Ertenli I, Kiraz S, Calgüneri M, Celik I, Erman M, Haznedaroglu IC, Kirazlı S (2001) Synovial fluid cytokine levels in Behcet’s disease. Clin Exp Rheumatol 19(Suppl24):S37–S41PubMed Ertenli I, Kiraz S, Calgüneri M, Celik I, Erman M, Haznedaroglu IC, Kirazlı S (2001) Synovial fluid cytokine levels in Behcet’s disease. Clin Exp Rheumatol 19(Suppl24):S37–S41PubMed
36.
go back to reference Karasneh J, Hajeer AH, Barrett J, Ollier WER, Thornhill M, Gül A (2003) Association of specific interleukin 1 gene cluster polymorphisms with increase susceptibility for Behçet’s disease. Rheumatolgy 42:860–864CrossRef Karasneh J, Hajeer AH, Barrett J, Ollier WER, Thornhill M, Gül A (2003) Association of specific interleukin 1 gene cluster polymorphisms with increase susceptibility for Behçet’s disease. Rheumatolgy 42:860–864CrossRef
Metadata
Title
Synovial proinflammatory cytokines and their correlation with matrix metalloproteinase-3 expression in Behçet’s disease. Does interleukin-1β play a major role in Behçet’s synovitis?
Authors
Salih Pay
Hakan Erdem
Aysel Pekel
Ismail Simsek
Ugur Musabak
Ali Sengul
Ayhan Dinc
Publication date
01-05-2006
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 7/2006
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-005-0040-0

Other articles of this Issue 7/2006

Rheumatology International 7/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.